Merck & Co Inc has discontinued two Phase 3 trials evaluating Keytruda (pembrolizumab) for the treatment of non-small cell lung cancer and cutaneous squamous cell carcinoma. The decision was based on recommendations from independent Data Monitoring Committees, which found that Keytruda did not demonstrate a statistically significant improvement in survival or recurrence-free survival compared to placebo.